Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease

Neuroscience Letters

Volumn 599, Issue , 2015, Pages 115-119

  Wang, Xuemei ^a   Yu, Shun ^b   Li, Fangfei ^a   Feng, Tao ^a,c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

Author keywords

Biomarker; Multiple system atrophy; Parkinson's disease; Red blood cells; Syn oligomer

Indexed keywords

ALPHA SYNUCLEIN; OLIGOMER; BIOLOGICAL MARKER; POLYMER;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PARKINSON DISEASE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME; UNIFIED PARKINSON DISEASE RATING SCALE; BLOOD; CASE CONTROL STUDY; CHEMISTRY; METABOLISM; MIDDLE AGED;

AGED; ALPHA-SYNUCLEIN; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ERYTHROCYTES; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYMERS;

EID: 84930642027     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2015.05.030     Document Type: Article

References (30)

1. Samii A., Nutt J.G., Ransom B.R. Parkinson's disease. Lancet 2004, 363:1783-1793.
2. Pahwa R., Lyons K.E. Early diagnosis of Parkinson's disease: recommendations from diagnostic clinical guidelines. Am. J. Managed Care 2010, 16(Suppl Implications):S94-S99.
3. Jellinger K.A. Neuropathological spectrum of synucleinopathies. Mov. Disord. 2003, 6(18 Suppl):S2-12.
4. Litvan I., Halliday G., Hallett M., Goetz C.G., Rocca W., Duyckaerts C., Ben-Shlomo Y., Dickson D.W., Lang A.E., Chesselet M.F., Langston W.J., Di Monte D.A., Gasser T., Hagg T., Hardy J., Jenner P., Melamed E., Myers R.H., Parker D., Price D.L. The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J. Neuropathol. Exp. Neurol. 2007, 66:251-257.
5. Hughes A.J., Ben-Shlomo Y., Daniel S.E., Lees A.J. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992, 42:1142-1146.
6. Kim S., Jeon B.S., Heo C., Im P.S., Ahn T.B., Seo J.H., Kim H.S., Park C.H., Choi S.H., Cho S.H., Lee W.J., Suh Y.H. Alpha-synuclein induces apoptosis by altered expression in human peripheral lymphocyte in Parkinson's disease. Faseb J. 2004, 18:1615-1617.
7. El-Agnaf O.M., Salem S.A., Paleologou K.E., Curran M.D., Gibson M.J., Court J.A., Schlossmacher M.G., Allsop D. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. Faseb J. 2006, 20:419-425.
8. Eller M., Williams D.R. Alpha-synuclein in Parkinson disease and other neurodegenerative disorders. Clin. Chem. Lab. Med. 2011, 49:403-408.
9. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
10. Wales P., Pinho R., Lazaro D.F., Outeiro T.F. Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration. J. Parkinsons Dis. 2013, 3:415-459.
11. Yasuda T., Nakata Y., Choong C.J., Mochizuki H. Neurodegenerative changes initiated by presynaptic dysfunction. Transl. Neurodegener. 2013, 2:16.
12. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
13. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., Levecque C., Larvor L., Andrieux J., Hulihan M., Waucquier N., Defebvre L., Amouyel P., Farrer M., Destee A. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
14. Mikkilineni S., Cantuti-Castelvetri I., Cahill C.M., Balliedier A., Greig N.H., Rogers J.T. The anticholinesterase phenserine and its enantiomer posiphen as 5'untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expression. Parkinsons Dis. 2012, 2012:142372.
15. Ohrfelt A., Grognet P., Andreasen N., Wallin A., Vanmechelen E., Blennow K., Zetterberg H. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?. Neurosci. Lett. 2009, 450:332-335.
16. Tokuda T., Qureshi M.M., Ardah M.T., Varghese S., Shehab S.A., Kasai T., Ishigami N., Tamaoka A., Nakagawa M., El-Agnaf O.M. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010, 75:1766-1772.
17. Shi M., Bradner J., Hancock A.M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Zabetian C.P., Kim H.M., Leverenz J.B., Montine T.J., Ginghina C., Kang U.J., Cain K.C., Wang Y., Aasly J., Goldstein D., Zhang J. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 2011, 69:570-580.
18. El-Agnaf O.M., Salem S.A., Paleologou K.E., Cooper L.J., Fullwood N.J., Gibson M.J., Curran M.D., Court J.A., Mann D.M., Ikeda S., Cookson M.R., Hardy J., Allsop D. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. Faseb J. 2003, 17:1945-1947.
19. Barbour R., Kling K., Anderson J.P., Banducci K., Cole T., Diep L., Fox M., Goldstein J.M., Soriano F., Seubert P., Chilcote T.J. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener. Dis. 2008, 5:55-59.
20. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 1992, 55:181-184.
21. Quinn N. Multiple system atrophy - the nature of the beast. J. Neurol. Neurosurg. Psychiatry 1989, (June 52 (Suppl)):78-89.
22. Yu S., Li X., Liu G., Han J., Zhang C., Li Y., Xu S., Liu C., Gao Y., Yang H., Ueda K., Chan P. Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody. Neuroscience 2007, 145:539-555.
23. Lohmann E., Thobois S., Lesage S., Broussolle E., du Montcel S.T., Ribeiro M.J., Remy P., Pelissolo A., Dubois B., Mallet L., Pollak P., Agid Y., Brice A. A multidisciplinary study of patients with early-onset PD with and without parkin mutations. Neurology 2009, 72:110-116.
24. Wickremaratchi M.M., Knipe M.D., Sastry B.S., Morgan E., Jones A., Salmon R., Weiser R., Moran M., Davies D., Ebenezer L., Raha S., Robertson N.P., Butler C.C., Ben-Shlomo Y., Morris H.R. The motor phenotype of Parkinson's disease in relation to age at onset. Mov. Disord. 2010, 26:457-463.
25. Lee P.H., Lee G., Park H.J., Bang O.Y., Joo I.S., Huh K. The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J. Neural. Trans. 2006, 113:1435-1439.
26. Foulds P.G., Yokota O., Thurston A., Davidson Y., Ahmed Z., Holton J., Thompson J.C., Akiyama H., Arai T., Hasegawa M., Gerhard A., Allsop D., Mann D.M. Post mortem cerebrospinal fluid alpha-synuclein levels are raised in multiple system atrophy and distinguish this from the other alpha-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. Neurobiol. Dis. 2012, 45:188-195.
27. Gao L., Tang H., Nie K., Wang L., Zhao J., Gan R., Huang J., Zhu R., Feng S., Duan Z., Zhang Y., Wang L. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis. Int. J. Neurosci. 2014, 10.3109/00207454.2014.961454.
28. Mondello S., Constantinescu R., Zetterberg H., Andreasson U., Holmberg B., Jeromin A. CSF alpha-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders. Parkinsonism Relat. Disord. 2014, 20:382-387.
29. Tokuda T., Salem S.A., Allsop D., Mizuno T., Nakagawa M., Qureshi M.M., Locascio J.J., Schlossmacher M.G., El-Agnaf O.M. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 2006, 349:162-166.
30. Hong Z., Shi M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Zabetian C.P., Leverenz J.B., Baird G., Montine T.J., Hancock A.M., Hwang H., Pan C., Bradner J., Kang U.J., Jensen P.H., Zhang J. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010, 133:713-726.